Philochem AG, part of the Philogen Group (MIL:PHIL), and RayzeBio, a subsidiary of Bristol-Myers Squibb (NYSE:BMY), announced ...

BMS entered the radiopharma space via its $4.1 billion buyout of RayzeBio at the end of 2023. Unlike Novartis’ approved ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the 15 best stocks to invest in for an 18 year old. On June 10, ...

OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in ...

Instead of homing in on PSMA—currently the most validated target in prostate cancer—BMS and Philochem will instead ...

The company is paying $350 million upfront, and potentially over $1.3 billion overall, for a radiopharmaceutical for prostate ...

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets ...

RayzeBio and Neumora Therapeutics have joined the public markets, and in contrast to the plethora of preclinical biotech IPOs of 2020 and 2021, these two Wall Street newcomers each have multiple ...

RayzeBio will also be participating in 1x1 investor meetings at these conferences. About RayzeBioRayzeBio is building a vertically integrated radiopharmaceutical therapeutics (RPT) company to ...

RayzeBio's stock has fallen near its original IPO price, presenting an attractive buying opportunity. RYZB's lead drug in Phase-3 clinical testing has best-in-class potential for the treatment of ...

With the RayzeBio deal, Bristol gains a late-stage targeted radiopharma therapy, RYZ101, that acts like a 'canon ball' to kill cancer cells by delivering radioactive particles to the tumorous ...